Brian Jaski, MD
Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1194706242
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $203,127 of the $234,770 with a category attached, or 86.5%. Boston Scientific accounts for 86.7% of it on its own, with 48 other manufacturers making up the rest. Among advanced heart failure and transplant cardiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 702 payments — averaging $334.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$204K
- Nuwellis, Inc.$11K
- Abbott$9K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Novartis$1K
- Abiomed$1K
- plus $7K from 43 others
Across 60 payments — averaging $7125.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$290K
- Abbott$111K
- Nuwellis, Inc.$27K
What the payments were for
- Consulting fees$203,12787%
- Speaking & faculty fees$13,5006%
- Travel & lodging$3,4021%
- Food & beverage$14,7296%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLINICAL TRIAL PRODUCT$93,703
- GENERAL - THERAPIES$16,122
- LUX-Dx Insertable Cardiac Monitor$15,828
- Aquadex$6,101
- AQUADEX SMARTFLOW CONSOLE$4,900
- HeartMate$4,775
- CardioMEMS HF System$1,704
- Impella$1,005
- HeartMate 3 Left Ventricular Assist Device$530
- Quadra Assura CRT Defibrillator$353
- RESOLUTE ONYX$179
- Vascular Lithotripsy$178
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$160
- FFRangio System$152
- Resolute$127
- ANDEXXA$126
- ENTRESTO$117
- AMVUTTRA$109
- GENERAL TACHY$107
- CARDIOMEMS$107
How this compares
$234,770 in reported general payments places this provider in the 90th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 145 | $193,791 |
| EntrestoSacubitril/Valsartan | 117 | $182,201 |
| XareltoRivaroxaban | 77 | $105,748 |
| JardianceEmpagliflozin | 55 | $75,069 |
| FarxigaDapagliflozin Propanediol | 75 | $64,042 |
| Repatha SureclickEvolocumab | 21 | $35,419 |
| BrilintaTicagrelor | 18 | $13,482 |
| EdarbiAzilsartan Medoxomil | 18 | $11,677 |
| Ezetimibe | 123 | $4,826 |
| Ranolazine ErRanolazine | 19 | $3,629 |
| Rosuvastatin Calcium | 188 | $3,461 |
| Metoprolol Succinate | 182 | $3,069 |
| Atorvastatin Calcium | 253 | $2,548 |
| Digoxin | 41 | $2,257 |
| Olmesartan Medoxomil | 81 | $2,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $529 | $193,791145 claims |
| NovartisEntresto | $1,375 | $182,201117 claims |
| Johnson & JohnsonXarelto | $176 | $105,74877 claims |
| AstraZenecaFarxiga, Brilinta | $546 | $77,52393 claims |
| Boehringer IngelheimJardiance | $179 | $75,06955 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $13 | $11,67718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Diego
- Hirsch MehtaSan Diego$494K
- Marcus UreySan Diego$341K
- Barry GreenbergSan Diego$270K
- Ajay SrivastavaSan Diego$203K
- Jorge Silva EncisoSan Diego$164K
- Burhan MohamedaliSan Diego$154K
- Hao TranSan Diego$147K
- Justin ParizoSan Diego$24K
- Eric AdlerSan Diego$24K
- Peter HoaglandSan Diego$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.